Fig. 7: STAND-A36 inhibits striatal dopamine release. | Nature Communications

Fig. 7: STAND-A36 inhibits striatal dopamine release.

From: An ultra-stable cytoplasmic antibody engineered for in vivo applications

Fig. 7

ae Intracellular expression of STAND-A36 decreases basal dopamine release in the striatum in vivo. a Microdialysis was performed in the striatum of the right cerebral hemisphere of mice 33 days after AAV injection into the SNc. b Average basal extracellular dopamine levels in the striatum of awake mice were measured every 10 min over a 60-min period using microdialysis (M4: n = 6 mice/group, A36: n = 7 mice/group, non-injected: n = 4 mice/group). Statistical analysis: two-tailed one-way ANOVA, F (2, 14) = 9.2457, P = 0.002757, A36 vs. M4, P = 0.0071; A36 vs. non-injected, P = 0.0079; M4 vs. non-injected, P = 0.9352. ce Total dopamine, dopamine metabolite (DOPAC and HVA) levels in the striatum and SNc of the right cerebral hemisphere of mice with or without an injection of AAV vectors (n = 6 mice/group). Statistical analysis: two-tailed one-way ANOVA, c Dopamine in striatum, F (2, 15) = 0.5833, P = 0.5702; dopamine in SN, F (2, 15) = 1.2156, P = 0.3241; d DOPAC in striatum, F (2, 15) = 0.99535, P = 0.392734; DOPAC in SN, F (2, 15) = 1.633946, P = 0.228045; e HVA in striatum, F (2, 15) = 1.0771461, P = 0.3655; HVA in SN, F (2, 15) = 1.1143889, P = 0.353814. Error bars represent standard error of the mean. Source data are provided as a Source Data file.

Back to article page